MA34805B1 - 4- (5-CYANO-PYRAZOLE-1-YL) -PIPERIDINE DERIVATIVES AS MODULATORS OF GPR119 - Google Patents
4- (5-CYANO-PYRAZOLE-1-YL) -PIPERIDINE DERIVATIVES AS MODULATORS OF GPR119Info
- Publication number
- MA34805B1 MA34805B1 MA35928A MA35928A MA34805B1 MA 34805 B1 MA34805 B1 MA 34805B1 MA 35928 A MA35928 A MA 35928A MA 35928 A MA35928 A MA 35928A MA 34805 B1 MA34805 B1 MA 34805B1
- Authority
- MA
- Morocco
- Prior art keywords
- gpr119
- pyrazole
- modulators
- cyano
- piperidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des composés qui modulent l'activité du GPR119, récepteur 119 couplé à la protéine G et leurs utilisations dans le traitement de maladies liées à la modulation du GPR119, récepteur 119 couplé à la protéine G chez des animaux.Compounds that modulate the activity of GPR119, G protein-coupled receptor 119 and their uses in the treatment of diseases related to the modulation of GPR119, G protein-coupled receptor 119 in animals.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41644110P | 2010-11-23 | 2010-11-23 | |
PCT/IB2011/054996 WO2012069948A1 (en) | 2010-11-23 | 2011-11-09 | 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34805B1 true MA34805B1 (en) | 2014-01-02 |
Family
ID=45418722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35928A MA34805B1 (en) | 2010-11-23 | 2011-11-09 | 4- (5-CYANO-PYRAZOLE-1-YL) -PIPERIDINE DERIVATIVES AS MODULATORS OF GPR119 |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP2643310A1 (en) |
JP (1) | JP2013543885A (en) |
KR (1) | KR20130083915A (en) |
CN (1) | CN103298801A (en) |
AP (1) | AP2013006809A0 (en) |
AR (1) | AR088121A1 (en) |
AU (1) | AU2011333427A1 (en) |
BR (1) | BR112013011865A2 (en) |
CA (1) | CA2814231A1 (en) |
CL (1) | CL2013001054A1 (en) |
CO (1) | CO6801716A2 (en) |
CR (1) | CR20130139A (en) |
CU (1) | CU20130059A7 (en) |
DO (1) | DOP2013000102A (en) |
EA (1) | EA201370118A1 (en) |
EC (1) | ECSP13012630A (en) |
GT (1) | GT201300135A (en) |
MA (1) | MA34805B1 (en) |
MX (1) | MX2013004083A (en) |
NI (1) | NI201300044A (en) |
PE (1) | PE20140409A1 (en) |
SG (1) | SG189830A1 (en) |
TW (1) | TWI433843B (en) |
UY (1) | UY33742A (en) |
WO (1) | WO2012069948A1 (en) |
ZA (1) | ZA201302362B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
WO2012170867A1 (en) | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
JP2017119628A (en) * | 2014-05-09 | 2017-07-06 | 日産化学工業株式会社 | Substituted azole compound and therapeutic agent for diabetes |
CN104892517A (en) * | 2015-02-13 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | Hydrazine compound, method for preparing same and application of hydrazine compound |
CN104592120A (en) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | Cyclopropyl hydrazide and methoxybenzene-containing GPR119 agonist as well as preparation method and application thereof |
CN104610151A (en) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | Compound containing hydrazide and alkoxy benzene structures as well as preparation method and application thereof |
EP3416959B1 (en) | 2016-02-18 | 2021-05-12 | Syngenta Participations AG | Pesticidally active pyrazole derivatives |
CN106631992B (en) * | 2017-01-05 | 2019-01-18 | 桑迪亚医药技术(上海)有限责任公司 | A kind of synthetic method of 4- oxygen -3,4- dihydro -2H- pyridine -1- t-butyl formate |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009014910A2 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders |
EP2280704B1 (en) * | 2008-03-31 | 2015-05-13 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds and uses thereof |
BRPI1014636A2 (en) * | 2009-06-05 | 2016-04-05 | Pfizer | gpr modulators 119 |
-
2011
- 2011-11-09 EP EP11802149.2A patent/EP2643310A1/en not_active Withdrawn
- 2011-11-09 JP JP2013540458A patent/JP2013543885A/en active Pending
- 2011-11-09 KR KR1020137013064A patent/KR20130083915A/en not_active Application Discontinuation
- 2011-11-09 AU AU2011333427A patent/AU2011333427A1/en not_active Abandoned
- 2011-11-09 MA MA35928A patent/MA34805B1/en unknown
- 2011-11-09 CN CN2011800550665A patent/CN103298801A/en active Pending
- 2011-11-09 SG SG2013023189A patent/SG189830A1/en unknown
- 2011-11-09 PE PE2013001058A patent/PE20140409A1/en not_active Application Discontinuation
- 2011-11-09 WO PCT/IB2011/054996 patent/WO2012069948A1/en active Application Filing
- 2011-11-09 CA CA2814231A patent/CA2814231A1/en not_active Abandoned
- 2011-11-09 BR BR112013011865A patent/BR112013011865A2/en not_active IP Right Cessation
- 2011-11-09 EA EA201370118A patent/EA201370118A1/en unknown
- 2011-11-09 MX MX2013004083A patent/MX2013004083A/en unknown
- 2011-11-09 AP AP2013006809A patent/AP2013006809A0/en unknown
- 2011-11-21 UY UY0001033742A patent/UY33742A/en unknown
- 2011-11-22 AR ARP110104351A patent/AR088121A1/en not_active Application Discontinuation
- 2011-11-22 TW TW100142804A patent/TWI433843B/en not_active IP Right Cessation
-
2013
- 2013-03-22 CR CR20130139A patent/CR20130139A/en unknown
- 2013-04-02 ZA ZA2013/02362A patent/ZA201302362B/en unknown
- 2013-04-16 CL CL2013001054A patent/CL2013001054A1/en unknown
- 2013-04-23 CU CU2013000059A patent/CU20130059A7/en unknown
- 2013-05-09 DO DO2013000102A patent/DOP2013000102A/en unknown
- 2013-05-13 NI NI201300044A patent/NI201300044A/en unknown
- 2013-05-20 EC ECSP13012630 patent/ECSP13012630A/en unknown
- 2013-05-21 GT GT201300135A patent/GT201300135A/en unknown
- 2013-05-23 CO CO13127143A patent/CO6801716A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2011333427A1 (en) | 2013-04-11 |
ZA201302362B (en) | 2014-06-25 |
KR20130083915A (en) | 2013-07-23 |
UY33742A (en) | 2012-06-29 |
TW201300373A (en) | 2013-01-01 |
TWI433843B (en) | 2014-04-11 |
CA2814231A1 (en) | 2012-05-31 |
CU20130059A7 (en) | 2013-06-28 |
DOP2013000102A (en) | 2013-07-15 |
AR088121A1 (en) | 2014-05-14 |
ECSP13012630A (en) | 2013-07-31 |
WO2012069948A1 (en) | 2012-05-31 |
CO6801716A2 (en) | 2013-11-29 |
AP2013006809A0 (en) | 2013-04-30 |
CN103298801A (en) | 2013-09-11 |
BR112013011865A2 (en) | 2016-08-23 |
CR20130139A (en) | 2013-06-28 |
PE20140409A1 (en) | 2014-03-23 |
NI201300044A (en) | 2013-08-01 |
EP2643310A1 (en) | 2013-10-02 |
MX2013004083A (en) | 2013-06-13 |
JP2013543885A (en) | 2013-12-09 |
CL2013001054A1 (en) | 2013-09-27 |
EA201370118A1 (en) | 2013-12-30 |
SG189830A1 (en) | 2013-06-28 |
GT201300135A (en) | 2015-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33334B1 (en) | L- (PIPERIDINE-4-YL) -PYRAZOLE DERIVATIVES AS MODULATORS OF GPR 119 | |
MA34805B1 (en) | 4- (5-CYANO-PYRAZOLE-1-YL) -PIPERIDINE DERIVATIVES AS MODULATORS OF GPR119 | |
EA201071245A1 (en) | NEW THERAPEUTIC APPROACHES FOR THE TREATMENT OF ALZGEYMER'S DISEASE AND RELATED DISTURBANCES THROUGH MODULATION OF THE STRESS RESPONSE | |
MA39088B1 (en) | Compositions and methods for modulating farnesoid x receptors | |
EA201001329A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
BRPI0808775A2 (en) | compounds and compositions as modulators of gpr119 activity | |
EA200901032A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
HN2010002774A (en) | DERIVATIVES OF 2- (1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL / 2-OXOIMIDAZOLIDIN-1-IL) PIRIDIN-4-CARBOXAMIDE ACTIVE AS ESTEAROIL-CoA MODULATORS | |
ATE478072T1 (en) | SPIROIMIDAZOLE DERIVATIVES AS PPAR MODULATORS | |
EA201001332A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
MA37525B1 (en) | Agents for the treatment of disorders involving modulation of ryanodine receptors | |
MA37739A1 (en) | Compounds and compositions for modulating the activity of egfr | |
EA201071243A1 (en) | COMBINED COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES WITH ZONISSMID AND ACAPROSAT | |
MA34474B1 (en) | AGONISTS OF GPR40 | |
EA201100138A1 (en) | 4-PHENOXYMETHYL-PIPERIDINES AS MODEL ACTIVITY GPR119 | |
EA201491530A1 (en) | MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION | |
NO20063191L (en) | Aminobenzazoles as P2Y1 Receptor Inhibitors | |
MA31683B1 (en) | Fxr modulation components and methods | |
EA201170349A1 (en) | MIF MODULATORS | |
ATE445624T1 (en) | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | |
EA201200570A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
MA33457B1 (en) | L-serine to be used as a drug for prevention | |
MA38076A1 (en) | Oxazolidin-2-one-pyrimidine derivatives | |
MA39171A1 (en) | Hydroxy formamide derivatives and their use | |
EA200970662A1 (en) | TRICYCLIC COMPOUNDS AND THEIR APPLICATION AS GLUCOCORTICOID RECEPTOR MODULATORS |